Needham & Company LLC Lowers Evolent Health (NYSE:EVH) Price Target to $4.00

Evolent Health (NYSE:EVH) had its target price decreased by research analysts at Needham & Company LLC from $15.00 to $4.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the technology company’s stock. Needham & Company LLC’s price target points to a potential upside of 20.12% from the company’s current price.

Several other analysts have also recently commented on the stock. Canaccord Genuity Group decreased their price target on shares of Evolent Health from $16.00 to $9.00 and set a “buy” rating on the stock in a research note on Friday, November 14th. Stephens raised Evolent Health from an “equal weight” rating to an “overweight” rating and set a $7.00 target price on the stock in a report on Thursday, November 13th. Truist Financial decreased their target price on Evolent Health from $16.00 to $10.00 and set a “buy” rating on the stock in a research report on Monday, November 10th. BTIG Research dropped their price target on Evolent Health from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Wednesday. Finally, Oppenheimer reduced their price objective on Evolent Health from $18.00 to $12.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 12th. Twelve research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $6.50.

Evolent Health Trading Up 6.1%

Shares of EVH opened at $3.33 on Wednesday. The company has a debt-to-equity ratio of 1.25, a current ratio of 1.33 and a quick ratio of 1.33. Evolent Health has a 1 year low of $2.50 and a 1 year high of $12.06. The company has a 50 day simple moving average of $3.50 and a two-hundred day simple moving average of $5.84. The firm has a market cap of $371.63 million, a P/E ratio of -0.65 and a beta of 0.27.

Evolent Health (NYSE:EVH) last released its earnings results on Tuesday, February 24th. The technology company reported $0.08 EPS for the quarter, topping the consensus estimate of $0.06 by $0.02. Evolent Health had a negative net margin of 28.49% and a positive return on equity of 1.30%. The firm had revenue of $468.72 million for the quarter, compared to the consensus estimate of $468.48 million. During the same quarter in the previous year, the firm earned ($0.02) earnings per share. The company’s quarterly revenue was down 27.5% compared to the same quarter last year. On average, equities analysts expect that Evolent Health will post 0.08 earnings per share for the current fiscal year.

Institutional Trading of Evolent Health

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Durable Capital Partners LP bought a new stake in Evolent Health in the second quarter worth $72,326,000. Rubicon Founders LLC purchased a new stake in shares of Evolent Health in the third quarter valued at $49,204,000. 8 Knots Management LLC bought a new stake in shares of Evolent Health in the 2nd quarter worth about $32,802,000. Eventide Asset Management LLC lifted its holdings in shares of Evolent Health by 54.0% in the 3rd quarter. Eventide Asset Management LLC now owns 6,292,511 shares of the technology company’s stock worth $53,246,000 after acquiring an additional 2,205,659 shares during the last quarter. Finally, Goldman Sachs Group Inc. boosted its stake in shares of Evolent Health by 162.2% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,836,402 shares of the technology company’s stock worth $26,861,000 after purchasing an additional 1,754,520 shares during the period.

Key Evolent Health News

Here are the key news stories impacting Evolent Health this week:

• Positive Sentiment: Q4 earnings beat — Evolent posted $0.08 EPS vs. consensus $0.06, turning profitable year-over-year and giving investors a near-term catalyst. Evolent Health (EVH) Q4 Earnings Top Estimates
• Positive Sentiment: Management to participate in investor conferences with live webcasts — increases visibility and gives investors direct access to management’s strategy and outlook. Evolent to Participate in Upcoming Investor Conferences
• Positive Sentiment: Some analysts maintain buy ratings and still show upside — BTIG (new $8 PT) and UBS (new $5 PT) kept buy calls, signaling continued institutional conviction despite lower targets. Evolent Health (NYSE:EVH) Given New $8.00 Price Target at BTIG Research
• Neutral Sentiment: Market commentary and analysis highlight turnaround potential and technical momentum — pieces noting EVH as “cheap, levered, but ready to rebound” and coverage of the intraday move provide narrative context rather than new fundamentals. Evolent Health: Cheap, Levered, But Ready To Rebound
• Neutral Sentiment: Investor note/roundups covering the share move summarize news flow for traders but don’t add new company data. Evolent Health (EVH) Shares Skyrocket, What You Need To Know
• Negative Sentiment: Multiple price-target cuts and a downgrade — several firms lowered PTs (Needham, Citi, RBC, UBS) and KeyCorp downgraded EVH to sector weight, which increases near-term downside risk and reflects investor concerns about top-line declines and leverage. Benzinga coverage of analyst actions
• Negative Sentiment: Revenue decline and margin pressure remain issues — revenue was roughly flat to consensus but down year-over-year, and the company still reports negative net margins, which could limit investor enthusiasm absent clear margin improvement. Evolent Health, Inc. Q4 2025 Earnings Call Transcript

Evolent Health Company Profile

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.